Phathom Pharmaceuticals (PHAT) to Post Earnings on Thursday

Phathom Pharmaceuticals (NASDAQ:PHAT) is expected to be releasing its Q2 2026 results before the market opens on Thursday, July 30th. Analysts expect Phathom Pharmaceuticals to post earnings of ($0.06) per share and revenue of $72.70 million for the quarter. Individuals are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Thursday, July 30, 2026 at 8:00 AM ET.

Phathom Pharmaceuticals Stock Performance

Phathom Pharmaceuticals stock traded down $0.12 during midday trading on Tuesday, hitting $11.83. 200,607 shares of the company’s stock were exchanged, compared to its average volume of 1,165,010. The company has a market cap of $943.51 million, a P/E ratio of -5.58 and a beta of 0.49. The stock has a 50-day moving average price of $10.87 and a two-hundred day moving average price of $11.84. Phathom Pharmaceuticals has a 52-week low of $8.02 and a 52-week high of $18.31.

Hedge Funds Weigh In On Phathom Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in PHAT. JPMorgan Chase & Co. boosted its position in Phathom Pharmaceuticals by 0.8% during the second quarter. JPMorgan Chase & Co. now owns 138,516 shares of the company’s stock valued at $1,328,000 after buying an additional 1,123 shares during the period. The Manufacturers Life Insurance Company increased its holdings in shares of Phathom Pharmaceuticals by 9.4% in the second quarter. The Manufacturers Life Insurance Company now owns 15,826 shares of the company’s stock worth $152,000 after buying an additional 1,364 shares during the period. Caitong International Asset Management Co. Ltd bought a new stake in shares of Phathom Pharmaceuticals in the 4th quarter valued at about $27,000. AQR Capital Management LLC lifted its stake in shares of Phathom Pharmaceuticals by 3.5% in the 4th quarter. AQR Capital Management LLC now owns 54,448 shares of the company’s stock valued at $903,000 after acquiring an additional 1,819 shares during the last quarter. Finally, Tower Research Capital LLC TRC increased its stake in Phathom Pharmaceuticals by 58.3% in the 2nd quarter. Tower Research Capital LLC TRC now owns 5,710 shares of the company’s stock worth $55,000 after purchasing an additional 2,102 shares during the period. Institutional investors own 99.01% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms have weighed in on PHAT. Weiss Ratings restated a “sell (d-)” rating on shares of Phathom Pharmaceuticals in a research report on Friday, July 17th. HC Wainwright reiterated a “buy” rating and set a $26.00 price objective on shares of Phathom Pharmaceuticals in a research report on Wednesday, June 17th. One equities research analyst has rated the stock with a Strong Buy rating, five have issued a Buy rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $24.50.

About Phathom Pharmaceuticals

Phathom Pharmaceuticals is a clinical‐stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases. The company’s core mission centers on addressing serious GI disorders by leveraging innovative mechanisms of action to improve patient outcomes. Phathom’s research and development efforts concentrate on conditions such as Helicobacter pylori infection, erosive esophagitis, gastroparesis and other functional GI disorders where significant unmet medical needs persist.

The company’s lead asset is vonoprazan, a potassium‐competitive acid blocker (P-CAB) licensed for use in the United States.